Dr. John Cush RheumNow
3 years 6 months ago
Retrospective cohort study of Taiwan Health Insurance Database looked at risk of #SLE in pts w/ Hashimoto’s thyroiditis (HT). Compared 15K HTvs 31K controls. SLE was incr in HT pts (IRR 3.58; p < 0.01). Several sensitivity analyses aHR 4.35 to 5.11 https://t.co/QaWEN4Chw9 https://t.co/bD8zrCJEXY
Dr. John Cush RheumNow
3 years 6 months ago
NLRP12 is a negative regulator of innate immune activation and type I interferon production. SLE PBMCs have low levels NLRP12 (inverse correl w/ IFNa & Hi Dz activity. NLRP12 knockouts or deficiency Incr autoAbs, inflammation & renal damage https://t.co/VICAqKmK9r https://t.co/MxqcNzh6BQ
Dr. John Cush RheumNow
3 years 6 months ago
New 5 Peptide Autoantibody Panel Complements RA Diagnosis
Antibodies to peptides not currently used for rheumatoid arthritis (RA) diagnosis helped identify patients with untreated early disease that conventional biomarkers missed, researchers said.
https://t.co/lOZvXBp7c1 https://t.co/6JVpeOyGYu
Medicare beneficiaries 65 and older with lupus faced dramatically higher mortality when they received no follow-up care during the month after a hospital stay, researchers found.
Death rates within 30 days of discharge were 65% higher in the absence of 30-day follow-up compared with older lupus patients who did receive it, according to Christie M. Bartels, MD, MS, of the University of Wisconsin in Madison, and colleagues.
Dr. John Cush RheumNow
3 years 7 months ago
Systemic Sclerosis cohort study of 506 SSc pts with saw 5.3 with Degos-like lesions (89% in fingers). Degos lesions more assoc w/ diffuseSSc & acro-osteolysis, digital ulcers, and calcinosis (but not renal crisis, ILD, or pulmonary HTN
https://t.co/eCumzZvEmO https://t.co/B41NLt4RYF
Dr. John Cush RheumNow
3 years 7 months ago
Multicenter study of 80 AOSD & 60 controls used to develop AOSD criteria:
- 3 pts rash
- 3pts fever ≥ 39C
- 2 pts pharyngitis
- 2 pts arthritis
- 2 pts NLR ≥ 4
- 1 pt glycosyl ferritin ≤ 20%
7 pts = Dx (sens 92.5%) vs Yamaguchi(79%), Fautrel (76%) https://t.co/UvtSABRs8s https://t.co/LzqWdyaj8h
Dr. John Cush RheumNow
3 years 7 months ago
Full read, solid review of Diagnosis and management of autoimmune hepatitis from BMJ https://t.co/mc1ozL6CG8 https://t.co/xQkX7WpETv
Dr. John Cush RheumNow
3 years 7 months ago
Pregnancy & RA: metanalysis of 9 studies, 12K RA pts met vs 10 million controls. RA preg have more maternal complications (C sect OR 1.55; preeclampsia OR, 1.6; preterm OR, 1.8) & neonatal probs (low gestat wt, ICU OR 1.34, & stillbirths OR, 1.99). https://t.co/1hA0zGsDtk https://t.co/awaV07GbEv
Dr. John Cush RheumNow
3 years 7 months ago
Join us on 3/18 and 3/19 in Dallas, Texas, or virtually for RheumNow Live! RheumNow Live is unlike any meeting you've ever attended.
Here's why:
-Inspired Education
-The Audience Matters
- A meeting designed to change your mind and practice.
https://t.co/wWjsjWATdv https://t.co/Rd7O3Yhpw3
Dr. John Cush RheumNow
3 years 7 months ago
Early ph II Pilot trial of 30 Systemic Sclerosis Pts using a new antifibrotic FT011 400mg vs 200mg v PBO x 12 wks showed CRISS score improved by 60% (400mg; (p=0.02 ) or 20% (200mg) at 12wks. An OL extension is planned for 9 mos @400 mg/d. https://t.co/ZU5wGXMDMC https://t.co/9kp20kfuCn
Dr. John Cush RheumNow
3 years 7 months ago
β-damascone, a major aroma from rose, was shown in animal models to dendritic cell -mediated immune functions, thusly demonstrating anti-inflammatory properties https://t.co/0w2b2dflkM https://t.co/zz0l7DJSY4
Dr. John Cush RheumNow
3 years 7 months ago
Know your numbers!!
Dr. Jack Cush reviews the news, journal articles and the numbers, from the past week on https://t.co/V10S4oVFsv.
https://t.co/xU0Ti4wwpq https://t.co/iQId9IDqHc
Dr. John Cush RheumNow
3 years 7 months ago
Serious Infection Risk in Pediatric Psoriasis with Ustekinumab, Etanercept, or MTX
This comparative analysis looks at the risk of SIE requiring hospitalization in pediatric PSO patients treated with ustekinumab, etanercept, or MTX prior to 2016.
https://t.co/kR14nrZzCo https://t.co/ccFJcO0eAj
Dr. John Cush RheumNow
3 years 7 months ago
The FDA has added a new indication to the oral JAK inhibitor Cibinqo (abrocitinib) - now approved to treat atopic dermatitis in adolescents 12 to under 18 years old. (Approval is based on a phase 3 JADE TEEN trial. https://t.co/DsQj3BfPmZ https://t.co/0bpb2FAwpg
Dr. John Cush RheumNow
3 years 7 months ago
An open-label trial of 170 adults w/ IgA Nephropathy (proteinuria >1 g/d) evaluated addition of mycophenolate to standard care (SC). MMF (1.5g/d) associated w/ less renal worsening - 7.1% MMF + SC vs. 21% SC alone (aHR 0.23; 95% CI, 0.09-0.63) https://t.co/FlcafoZi3U https://t.co/tQkZE8RRyy

